Oncology News | pharmaphorum

News

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

News

Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.

News

Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.

News

BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

News

The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer.

News

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?